These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. Kitano A; Shimasaki T; Chikano Y; Nakada M; Hirose M; Higashi T; Ishigaki Y; Endo Y; Takino T; Sato H; Sai Y; Miyamoto K; Motoo Y; Kawakami K; Minamoto T PLoS One; 2013; 8(2):e55289. PubMed ID: 23408967 [TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894 [TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. Mamaghani S; Patel S; Hedley DW BMC Cancer; 2009 Apr; 9():132. PubMed ID: 19405981 [TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499 [TBL] [Abstract][Full Text] [Related]
6. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023 [TBL] [Abstract][Full Text] [Related]
7. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway. Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057 [TBL] [Abstract][Full Text] [Related]
8. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis. Guo HC; Bu HQ; Luo J; Wei WT; Liu DL; Chen H; Tong HF; Wang ZH; Wu HY; Li HH; Zuo MM; Li W; Lin SZ Int J Oncol; 2012 Jun; 40(6):1849-57. PubMed ID: 22378302 [TBL] [Abstract][Full Text] [Related]
9. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Ougolkov AV; Fernandez-Zapico ME; Bilim VN; Smyrk TC; Chari ST; Billadeau DD Clin Cancer Res; 2006 Sep; 12(17):5074-81. PubMed ID: 16951223 [TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159 [TBL] [Abstract][Full Text] [Related]
11. Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. Jiang PH; Motoo Y; Sawabu N; Minamoto T World J Gastroenterol; 2006 Mar; 12(10):1597-602. PubMed ID: 16570353 [TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834 [TBL] [Abstract][Full Text] [Related]
14. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965 [TBL] [Abstract][Full Text] [Related]
15. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases. Yeo D; Huynh N; Beutler JA; Christophi C; Shulkes A; Baldwin GS; Nikfarjam M; He H Cancer Lett; 2014 May; 346(2):264-72. PubMed ID: 24491405 [TBL] [Abstract][Full Text] [Related]
16. Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity. Ou YQ; Zhu Wb; Li Y; Qiu PX; Huang YJ; Xie J; He SM; Zheng XK; Leng TD; Xu D; Yan GM Acta Pharmacol Sin; 2010 Jan; 31(1):73-80. PubMed ID: 19966835 [TBL] [Abstract][Full Text] [Related]
17. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer. Paik WH; Ryu JK; Jeong KS; Park JM; Song BJ; Lee SH; Kim YT; Yoon YB World J Gastroenterol; 2014 Jul; 20(26):8545-57. PubMed ID: 25024609 [TBL] [Abstract][Full Text] [Related]
18. GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. Watson RL; Spalding AC; Zielske SP; Morgan M; Kim AC; Bommer GT; Eldar-Finkelman H; Giordano T; Fearon ER; Hammer GD; Lawrence TS; Ben-Josef E Neoplasia; 2010 May; 12(5):357-65. PubMed ID: 20454507 [TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression. Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M HPB (Oxford); 2015 Sep; 17(9):770-6. PubMed ID: 26147011 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression. Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]